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Background The current strategy utilized by WHO/United Nations Children’s
Fund (UNICEF) to reach the Global Immunization Vision and
Strategy 2010 measles reduction goal includes increasing coverage
of measles vaccine, vitamin A treatment and supplementation in
addition to offering two doses of vaccine to all children.
Methods We conducted a systematic review of published randomized con-
trolled trials (RCTs) and quasi-experimental (QE) studies in order
to determine effect estimates of measles vaccine and vitamin
A treatment for the Lives Saved Tool (LiST). We utilized a standard-
ized abstraction and grading format in order to determine effect
estimates for measles mortality employing the standard Child
Health Epidemiology Research Group Rules for Evidence Review.
Results We identified three measles vaccine RCTs and two QE studies with
data on prevention of measles disease. A meta-analysis of these
studies found that vaccination was 85% [95% confidence interval
(CI) 83–87] effective in preventing measles disease, which will be
used as a proxy for measles mortality in LiST for countries vacci-
nating before one year of age. The literature also suggests that a
conservative 95% effect estimate is reasonable to employ when vac-
cinating at 1 year or later and 98% for two doses of vaccine based
on serology reviews. We included six high-quality RCTs in the
meta-analysis of vitamin A treatment of measles which found no
significant reduction in measles morality. However, when stratify-
ing by vitamin A treatment dose, at least two doses were found to
reduce measles mortality by 62% (95% CI 19–82).
Conclusion Measles vaccine and vitamin A treatment are effective interventions
to prevent measles mortality in children.
Keywords Measles, vaccine, vitamin A, treatment
Background
In 2005, the World Health Assembly set a goal of a
90% reduction in measles mortality by 2010 compared
with 2000 levels as a part of the Global Immunization
Vision and Strategy (GIVS).
1 WHO and UNICEF have
instituted a multi-component strategy in 47 priority
countries with high measles burden including: reach-
ing and maintaining 590% coverage for first dose
measles vaccine by 12 months of age, providing
appropriate clinical management including vitamin
A treatment, enhancing effective measles surveillance,
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i48and monitoring vaccination coverage.
2 In addition,
the Strategic Advisory Group of Experts on
Immunization recently put forth a global recommen-
dation that all children should receive 2 doses of
measles vaccine.
3 Maintaining high vaccination cover-
age is also central to measles control efforts in coun-
tries with relatively low measles burden, and many of
these countries will need to increase coverage in order
to reach measles elimination goals.
The effectiveness of measles vaccination is based on
several host and vaccine factors.
4 The most important
factors are age at vaccination and receipt of a second
dose.
5 WHO recommends first dose measles vaccina-
tion at 9 months of age in many developing countries
with a high risk of measles morbidity and mortality
during the first year of life.
6 Since 2000, the WHO has
also recommended that all children receive a second
opportunity for measles vaccination.
2 Most developed
countries with low levels of measles transmission
vaccinate at 1 year of age or later to minimize the
risk of maternal antibody interference, and many
have implemented a two-dose schedule. Therefore,
the effectiveness of measles vaccine to prevent
measles mortality is not uniform worldwide and will
vary based on vaccine schedule recommendations
and programme implementation strategies. The
WHO also recommends vitamin A treatment of mea-
sles consisting of two doses of 50000 IU for infants
<6 months of age, 100000 IU for those 6 months to
1 year of age, and 200000 IU for individuals 41 year
of age.
7 Routine vitamin A supplementation is
also thought to decrease measles case fatality in
addition to likely reducing mortality from multiple
factors, including diarrhoea.
8 The comprehensive
Lives Saved Tool (LiST) review of vitamin A supple-
mentation on multiple causes of death determined
supplementation decreased measles-specific mortality
by 19%.
9
Multiple reviews of measles vaccine and vitamin
A treatment effectiveness have been published.
10–13
However, most measles vaccine reviews have emp-
loyed serologic data to determine effect estimates for
measles-specific mortality. The most recent Cochrane
review for vitamin A treatment of children with mea-
sles erroneously includes a supplementation trial;
therefore, we have revised the analysis excluding
this trial.
13,14 Here, we present our systematic review
of measles vaccine and vitamin A treatment in order
to determine effect estimates and corresponding
uncertainty for the LiST.
Methods
We systematically reviewed all published literature
from 1960–2008 to identify studies of measles vaccine
and vitamin A treatment. As per the Child Health
Epidemiology Research Group (CHERG) systematic
review guidelines, PubMed, Cochrane Libraries, and
all WHO Regional Databases were searched in all
languages.
15 The search terms for measles vaccine
studies included combinations of ‘measles vaccine’,
‘trial’, ‘effect ’, ‘effica ’, ‘mortality’, and ‘non-specific’.
The vitamin A treatment search terms included: ‘vita-
min A’, ‘trial’, ‘effect ’, ‘effica ’, ‘mortality’ and ‘mea-
sles’. Studies abstracted for analysis included
randomized controlled trials (RCT) and quasi-experi-
mental (QE) studies due to a priori knowledge of
these high-quality studies. Observational studies
were included in the all-cause mortality analysis for
measles vaccine due to minimal data from RCTs or
QE studies. Three studies reported data for two dis-
tinct study cohorts using different methods; therefore
we chose to analyse the cohorts separately and when
referencing these studies denote cohort ‘a’ and ‘b’.
16–
18 If two or more studies presented data for the same
population during the same time period, the most
applicable study based on methods and analysis was
included in the meta-analyses. Studies using high-
titre measles vaccine were excluded as this vaccine
was associated with increased mortality in girls.
19
All studies which met final inclusion and exclu-
sion criteria were double data abstracted into a
standardized form for each outcome of interest.
15
We abstracted key variables with regard to the study
identifiers and context, study design and limita-
tions, intervention specifics, and outcome effects.
Each study was assessed and graded according to
the CHERG adaptation of the Grades of Recommen-
dation, Assessment, Development and Evaluation
(GRADE) technique.
20 Randomized or cluster rando-
mized trials received an initial score of ‘high’. The
grade was decreased one grade for each study
design limitation. In addition, studies reporting an
intent-to-treat analysis or with statistically significant
strong levels of association (480% reduction) received
1–2 grade increases. Any study with a final grade of
‘very low’ was excluded.
For any outcome with more than one study, we
conducted a meta-analysis and reported the Mantel–
Haenszel pooled relative risk (RR) and corresponding
95% confidence interval (CI). When there was heter-
ogeneity, the DerSimonian–Laird pooled RR and cor-
responding 95% CI were reported. If zero events
occurred in a treatment group, 0.5 was added to
both the treated and untreated event total in order
to compute a 95% CI and corresponding P-value. In
the meta-analysis of studies with data on the effect of
measles vaccine on measles mortality, there were no
deaths among the vaccinated; therefore, we chose not
to compute an effect estimate with confidence inter-
vals since our method to account for zero events
would significantly lower the effect estimate. Results
are expressed in terms of relative benefit (1–RR),
which is more commonly defined as efficacy or effec-
tiveness. All analyses were conducted using STATA 10
SE statistical software.
We summarized the evidence by intervention and
outcome including a qualitative assessment of the
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standard guidelines
15 for each outcome. The CHERG
Rules for Evidence Review
20 were applied to the col-
lective measles vaccine and vitamin A treatment data
to generate estimates for the effect on measles
mortality.
Results
We identified 3179 titles from searches in all data-
bases for measles vaccine. After screening, we
included three studies with measles-specific mortality
data,
16a,16b,21 23 studies of all-cause mortal-
ity,
16b,17,22–41 and nine studies which reported measles
disease as an outcome
16a,16b,18,21,42–45 in the final
database (Supplementary Table 1). In Table 1, we
report the quality assessment of measles vaccine stu-
dies by outcome, as well as results from correspond-
ing meta-analyses. In the two RCTs and one QE study
with measles specific mortality, no measles deaths
occurred in the vaccinated.
16a,16b,21 Next, we included
studies that attempted to control for confounding in
our meta-analysis for the effect of measles vaccine on
all-cause mortality. Thirteen observational studies
25–
27,31–33,37,39–41 and one RCT
16b met these requirements
and the results indicate that measles vaccine was
associated with a reduction in all-cause mortality of
43% (29–54). Four studies in the original database
were excluded from the meta-analysis of vaccination
effect on measles disease: an RCT which noted
differential misclassification of measles disease by
vaccination status, an RCT that administered
immunoglobulin to children in contact with measles,
a QE study where a proportion of measles vaccine
administered was not potent due to improper storage,
and a QE study which did not publish the number of
trial participants or confidence interval.
16b,43,44,18b The
five remaining studies, three RCTs and two QE stu-
dies, found that a single dose of measles vaccine
reduced measles disease by 85% (95% CI 83–87)
(Figure 1).
16a,21,42,18a,45
A total of 270 titles were identified for evaluation of
vitamin A treatment. We included seven studies, six
RCTs and one QE, in the final database for vitamin A
treatment of measles
46–52 (Supplementary Table 2).
The Ellison study was excluded from meta-analyses
Table 1 Quality of evidence assessment for measles vaccine
Quality assessment Summary of findings
Directness No of events
No. of
studies
(ref.) Design Limitations Consistency
Generalizability
to population
of interest
Generalizability
to intervention
of interest Intervention Control
Relative
benefit
a
(95% CI)
Measles Mortality: high outcome-specific quality
3 (16a,
16b, 21)
2 RCT
1Q E
None NA No studies
in Asia
( 0.5)
Generalizable 0 14 100% (NC)
All-cause Mortality: low outcome-specific quality
14 (16b,
25–27,
31–33, 35–41)
1 RCT
8P C
2R C
3C C
None Heterogeneity
( 0.5)
Generalizable Generalizable 297 164 43% (29–54)
b
Measles Disease: high outcome-specific quality
5 (16a,
18a, 21,
42, 45)
3 RCT
2Q E
None No Heterogeneity Generalizable Generalizable 203 2238 85% (83–87)
c
NC, not calculated.
aRelative benefit is 1–RR.
bCalculated with DerSimonian–Laird method.
cCalculated with Mantel–Haenszel method.
Figure 1 Forest plot for the effect of one dose measles
vaccine on measles disease (vaccinated compared with
unvaccinated). Heterogeneity 
2¼3.59 (df¼4); P¼0.464.
I
2 (variation in RR attributable to heterogeneity)¼0.0%.
Test of RR¼1: z¼26.34; P<0.01
i50 INTERNATIONAL JOURNAL OF EPIDEMIOLOGYdue to lack of randomization and the use of a smaller
dose of vitamin A ( 3000 IU) compared with the
RCTs.
52 A meta-analysis of the six high-quality RCTs
found no significant reduction in measles mortality
[RR 0.63; 95% CI (0.37–1.08)] (Table 2).
46–51
However, when stratifying the analysis by vitamin A
treatment dose, at least two doses of 200000 IU for
children41 year and 100000 IU for infants, treatment
was found to reduce measles mortality (RR 0.38; 95%
CI 0.18–0.81) (Figure 2).
46–48
Discussion
The WHO estimated that 750000 measles deaths
occurred worldwide in 2000 and decreased to
197000 in 2007.
53 This substantial reduction is largely
due to intense efforts from WHO/UNICEF and other
programmes to provide vitamin A supplementation
and treatment as well as increase coverage of
measles vaccine including offering a second opportu-
nity for vaccination in countries with a high measles
burden.
Live attenuated measles vaccine was first introduced
in the United States and many developed countries
during the 1960s; licensure was based on preven-
tion of measles disease and immunologic corre-
lates of immunity as the primary outcomes.
54–56
Our systematic review identified three RCTs identify-
ing measles-specific mortality as an endpoint. Only
14 measles deaths occurred in the three trials com-
bined (all in the unvaccinated group) and following
the CHERG Rules for Evidence Review, we were
not able to determine a direct effect estimate.
57
Observational studies, in addition to RCTs, were
included in the all-cause mortality analysis to address
the hypothesis that measles vaccine has an effect on
non-measles mortality.
58 Our meta-analysis found
that measles vaccine reduced all cause mortality by
43% (29–54), but the quality of evidence is graded
low per CHERG rules due to a majority of data arising
from observational studies, which are prone to sur-
vival bias and possibly other forms of unrecognized
bias. Due to inconclusive evidence for a non-specific
effect of measles vaccine on all cause mortality, this
assessment will not be included in this edition of
LiST. We included three RCTs and two QE studies
in the meta-analysis of vaccination effect on measles
disease. These studies found that measles vaccine
reduced measles disease by 85% (95% CI 83–87) and
per Rule 7, this effect size will be used in the LiST
tool as a proxy for prevention of measles mortality.
Numerous methodologically sound observational
studies have also been published with data on the
effectiveness of measles vaccine; however, per LiST
rules these studies are graded as ‘low’ and are
Table 2 Quality of evidence assessment for vitamin A treatment for measles
Quality assessment Summary of findings
Directness No of events
No. of
studies
(ref.) Design Limitations Consistency
Generalizability
to population
of interest
Generalizability
to intervention
of interest Intervention Control
Relative
benefit
a
(95% CI)
Measles Mortality: moderate outcome specific quality
5 (46–51) RCT None No heterogeneity Only African
studies
( 0.5)
Different doses
of vitamin A
( 0.5)
19 33 37% ( 8t o6 3 )
b
Measles mortality (At least two doses of 200000 IU for children and 100000 IU for infants): moderate outcome specific quality
3 (46–48) RCT <50 events ( 0.5)
c No heterogeneity Only African
studies ( 0.5)
Generalizable 8 23 62% (19 to 82)
b
NC, not calculated.
aRelative benefit is 1–RR.
bCalculated with Mantel–Haenszel method
cDeduction to account for Rule 0 of CHERG Rules for Evidence Review.
Figure 2 Forest plot for the effect of vitamin A treatment
on measles mortality for at least two doses of 200000 IU for
children and 100000 IU for infants (treated vs untreated).
Heterogeneity 
2¼1.05 (df¼2); P¼0.592. I
2 (variation in
RR attributable to heterogeneity)¼0.0%. Test of RR¼1:
z¼2.50; P¼0.01
EFFECTIVENESS OF MEASLES VACCINATION AND VITAMIN A TREATMENT i51considered weaker sources of evidence in comparison
to RCTs. Furthermore, a pooled estimate of well-
conducted observational studies would likely underes-
timate the true efficacy of measles vaccine. A substan-
tial proportion of published observational studies were
conducted during measles outbreaks which can occur
as a result of decreased vaccine efficacy attributable
to improper vaccine storage or vaccination of children
before recommended age.
5
Our effect estimate is consistent with the Cutts
serology review which estimated seroconversion
rates of 85% when vaccine is administered prior
to one year and the Singh review which estimated
effectiveness of 85–90% based on feasibility studies
conducted in India.
10,11 Our effect findings and corre-
sponding uncertainty are applicable to real world
vaccine programmes in developing countries as
children are vaccinated at a wide range of ages.
The studies included in our analysis vaccinated
children between 6 months and 5 years. However,
this estimate is likely conservative for the effect of
vaccination on measles mortality since several studies
have documented that previously vaccinated children
who develop measles have reduced rates of complica-
tions compared with unvaccinated children.
59–61 None
of the trials in our meta-analysis specifically address
current vaccination programmes in developed coun-
tries, where the recommended age of vaccination is
usually at 512 months of age. Measles vaccine
is more effective when administered to older children
as maternal antibodies that can interfere with devel-
opment of immunity are usually absent.
62 The WHO
SAGE recently recommended that countries with low
levels of measles transmission increase the age at
administration of the first dose of vaccine from 9 to
12 months in addition to providing a routine second
dose during the second year of life.
3 Approximately,
95% of individuals seroconvert when measles vaccine
is administered at one year of age or older.
63,64
Therefore, if the LiST tool is used to estimate measles
mortality effect in countries vaccinating at one year
or greater, the user may want to increase the effect
estimate for measles vaccine. In addition, we chose
not to include herd immunity in the default LiST esti-
mates for single dose vaccine. The reproductive
number (R0) for measles is 15–20 and495% of a pop-
ulation is needed to be immune in order to stop ende-
mic transmission.
65 Furthermore, these immune
individuals will have to be equally dispersed in the
population, an assumption we are not willing to
make especially since most developing countries
have not reached 490% coverage. However, LiST
users have the capacity to adjust the effectiveness of
measles vaccination by coverage level, and we support
users adjusting country specific effect estimates to
100% if strong surveillance data indicate no measles
transmission.
The effect of a second dose of measles vaccine
on measles disease or mortality compared with no
vaccination has not been evaluated on individual
children in prospective randomized studies as this
type of trial would be unethical. Therefore, the best
estimate of the effect of a two-dose measles vaccine
schedule on measles mortality must be extrapolated
from serology data, studies looking at effectiveness
of two dose vs one-dose measles vaccination, and
observational studies. Caution should be taken when
using serology data to estimate the impact on mortal-
ity. A recent WHO review of serology studies deter-
mined that a median 97% [inter-quartile range (IQR)
87–100%] of children that failed to seroconvert to first
dose measles vaccine developed immunity after a
second dose.
64 If 85% efficacy is assumed for single
dose measles vaccine, these serology results would
correlate to an efficacy of 99.6% for two dose measles
vaccine with a range of 98.1–100% based on the IQR
of the review. In addition, the effectiveness of two
doses of measles vaccine will vary by setting based
on the age of vaccination. Epidemiologic studies com-
paring the effectiveness of early two dose vaccination
vs single dose have found varying results in develop-
ing country settings; a study in Niger found two doses
(first dose at 6–8 months and second at 9 months)
was 23% less effective than single dose whereas stu-
dies in India (first dose at 9–12 months and second at
15–18 months) and Guinea Bissau (first dose at 6–8
months and second at 9–12 months) determined two
doses of vaccine were respectively 83 and 90% more
effective than one dose of measles vaccine.
66–69 In
order to produce a conservative estimate of the effi-
cacy of two dose measles vaccine per LiST rules, we
felt an input of 98% based on the lower quartile of the
WHO two dose measles vaccine serology review was
reasonable.
Vitamin A deficiency is a recognized risk factor
for severe measles and since 1987 the WHO and
UNICEF have recommended vitamin A treatment
of children with measles.
70 We performed a
meta-analysis of six vitamin A treatment RCTs
with measles-specific mortality data and found no
significant reduction in measles morality [RR 0.63;
95% CI (0.37–1.08)]. However, when stratifying the
analysis by vitamin A treatment dose, at least two
doses of 200000 IU for children 51 year of age and
100000 IU for infants was found to reduce measles
mortality by 62% [RR 0.38; 95% CI (0.18–0.81)].
These results support the current recommendation
that two doses of vitamin A be offered to children
with measles.
7 An exception to Rule 0 (at least
50 deaths needed) was deemed appropriate with
support of CHERG due to the high quality evidence
from three RCTs. As a result, a 62% effect estimate
with corresponding uncertainty will be used in the
LiST tool.
i52 INTERNATIONAL JOURNAL OF EPIDEMIOLOGYThe results of our review, which are the default
effectiveness values included in LiST, are summarized
in Figure 3. Our results support the current strategy
of WHO/UNICEF to reduce measles mortality
in priority countries, which includes increasing cover-
age of measles vaccine and vitamin A in addition
to offering a second opportunity for vaccination to
all children. The GIVS 2010 goals for measles seem
to be within reach and hopefully with offering two
dose measles vaccine in the South-East Asian region
a 90% reduction in measles mortality will be
accomplished.
Supplementary data
Supplementary data are available at IJE online.
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